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a b s t r a c t
Studies were conducted in New Zealand White rabbits to assess the seminal transfer, vaginal absorp-
tion, and placental transfer of a therapeutic monoclonal antibody (T-IgG4). T-IgG4 was administered by
intravenous injection (IV) in males and by IV and intravaginal routes in females. Low levels of T-IgG4
were excreted into seminal plasma (100- to 370-fold lower than serum concentrations) and absorbed
following vaginal dosing (three orders of magnitude lower than IV administration). On gestation day 29
(GD29), fetal serumT-IgG4 levelswere 1.5-fold greater thanmaternal levels following IV dosing. The fetal
T-IgG4 exposure ratio for seminal transfer vs. direct maternal IV dosing was estimated to be 1.3×10−8.
Applying human serum T-IgG4 exposure data to the model, the estimated human T-IgG4 serum concen-
−7
lacental transfer
eminal transfer
aginal absorption
tration from seminal transfer was 3.07×10 g/mL, an exposure level at least 1000-fold lower than the
T-IgG4-ligand dissociation constant (Kd) and at least seven orders of magnitude lower than the in vivo
concentration producing 20% inhibition of the target (EC20). These data indicate that excretion of a T-IgG4
into semen would not result in a biologically meaningful exposure risk to the conceptus of an untreated
partner.. Introduction
The potential for drugs and other chemicals to be excreted into
emen at concentrations sufﬁcient to adversely affect sperm func-
ionordevelopmentof theembryoor fetushasbeena topicdebated
n the scientiﬁc literature over the past few decades. Two excel-
ent reviews on this subject are presented by Pichini et al. [1] and
lemmt and Scialli [2]. The review by Pichini et al. [1] covers a
ariety of important topics that includes the pharmacokinetics of
mall molecular weight drug excretion into seminal ﬂuid across a
road spectrum of therapeutic drug classes. Although most of the
mallmolecularweight drugswere reported to bepresent in semen
t concentrations less than that observed in plasma, some of the
ntimicrobials were found to concentrate in semen. Clindamycin
or examplewas reported in human seminal ﬂuid at concentrations
pproximately 11-fold higher than plasma [3]. The demonstrated
oncentration of some drugs in semen increases the concern for
otential adverse reproductive and developmental effects from
ither direct damage to sperm or from the seminal transfer of drug
rom treated males to untreated female partners. Although the
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C0730, Indianapolis, IN 46285, USA. Tel.: +1 317 433 3601; fax: +1 317 260 7040.
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effect of direct drug exposure onmale fertility and early embryonic
development can be assessed through standard nonclinical fertility
study protocols, such as that described for male fertility assess-
ment in ICH S5(R2) [4], the developmental effects from seminal
drug transfer to the untreated female is not routinely evaluated.
To address the potential exposure risk from seminal transfer
of chemicals to the conceptus, Klemmt and Scialli [2] provided
a female/conceptus exposure assessment based on a worst-case
scenario using measured clindamycin seminal concentrations of
0.125mg/mL, a semen volume of 5mL, 100% vaginal absorption,
and a volume of distribution of 1.1 L/kg for a 60kg woman. The
blood concentration of clindamycin in a woman exposed through
semen was calculated to be three orders of magnitude lower than
the blood exposure of the treated man who produced the semen.
The resulting blood concentration in the femalewas thought not to
have clinical relevance.
Despite the ﬁndings reported by Klemmt and Scialli [2] that
predict a low exposure risk, there remain safety concerns for the
transfer of drugs through semen. Relatively recently, the United
Kingdom [5] issued guidance on the use of contraception in human
clinical trials in which they state, “Where there is a risk of drug
secretion through the ejaculate, male subjects (includingmenwho
have had vasectomies) whose partners are pregnant should use
condoms for the duration of the study and for a suitable time after-
wards (e.g. ﬁve half-lives). The barrier protection requirements for
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en are to ensure that the fetus is not exposed to the investiga-
ional medical product through seminal transfer and subsequent
aginal absorption.” In addition, the literature surrounding semi-
al excretion and vaginal absorption of drugs primarily addresses
mall molecules and does not cover the risk of biopharmaceuticals
resent in seminal ﬂuid [1,2]. The lack of data on seminal transfer
nd vaginal absorption of biopharmaceuticals represent a signiﬁ-
ant data gap given the high proportion of drugs that fall into this
ategory.
In order to assess the potential fetal exposure risk due to the
eminal transfer of a therapeutic IgG4 antibody drug (T-IgG4), a
eries of studies were conducted to assess seminal excretion, vagi-
al vs. intravenous absorption, and placental transfer of a T-IgG4
ntibody.
. Materials and methods
.1. General methodology
.1.1. Animal care
New Zealand White (NZW) rabbits were obtained from Cov-
nce Research Products, Incorporated (Kalamazoo, MI or Denver,
A). Each rabbit was uniquely identiﬁed by number using a plastic
ar tag. The rabbits were individually housed in clean suspended
tainless steel cages in an environmentally controlled room dur-
ng the study. The room temperature and humidity controls were
et to maintain environmental conditions of 66±5 ◦F (19±3 ◦C)
nd 50±20% relative humidity. Temperature and relative humid-
ty were monitored continuously. Fluorescent lighting controlled
y light timers provided illumination for a 12-h light/dark pho-
operiod. The ventilation rate was set at a minimum of 10 room air
hanges per hour. Reverse osmosis-puriﬁedwater was available ad
ibitum. PMI Nutrition International, LLC Certiﬁed Rabbit LabDiet®
322 was offered ad libitum throughout the acclimation and study
eriod. Periodic analyses of the certiﬁed feed were performed by
he manufacturer to ensure that heavy metals and pesticides were
ot present at concentrations that would be expected to affect
he outcome of the study. In the event of inappetence, kale was
rovided as a supplement. Clinical signs were monitored prior to
nd 1-h post-dose and daily thereafter. Concentrations of T-IgG4
n serum and seminal plasma were determined by enzyme-linked
mmunosorbent assays (ELISA) using a validated method.
.1.2. Bioanalytical methodology for the measurement of T-IgG4
ELISA methods were validated that involved the capture of
uman T-IgG4 from matrix (either rabbit serum or rabbit semi-
al plasma) onto human T-IgG4-coated plates. Mouse anti-human
gG-HRP conjugate was used to detect the bound T-IgG4. For the
abbit serum assay, the range of quantiﬁcation was from 0.015
o 0.96g/mL. For the rabbit seminal plasma assay, the range of
uantitationwas0.012–0.256g/mL. Sampleswith concentrations
bove the validation range were measured following dilution. In
abbit serum and in rabbit seminal plasma, stability was demon-
trated for up to three freeze–thaw cycles and in thawed samples
or at least 17h at ambient temperature. Long-term freezer stabil-
ty was established at approximately −70 ◦C for 372 days in rabbit
erum and for 298 days in rabbit seminal plasma. All samples were
nalyzed within the validated limits. For both assays, intra-run
recision (% relative standard deviation, or %RSD) and accuracy
% relative error, or %RE) was ≤19%, and inter-run precision and
ccuracy was ≤17%. Data were evaluated and are presented using
escriptive statistics that include mean, standard deviation (S.D.)
r standard error (S.E.), and the number of animals (N) used to
alculate the mean. No comparative statistics were conducted.xicology 48 (2014) 124–131 125
2.2. Seminal excretion of T-IgG4 in male rabbits
Fifteen male NZW rabbits, approximately 15 months old and
weighing approximately 3.2–4.0 kg were randomly assigned to
three groups of ﬁve rabbits; 0 (vehicle control), 6, and 100mg/kg
T-IgG4. The T-IgG4 dosing solutions were prepared in an aque-
ous diluent containing 10mM sodium citrate, 150mM sodium
chloride, and 0.02% polysorbate 80 (pH 6.0) to obtain dosing con-
centrations of 0 (vehicle control), 1.2mg/mL (6mg/kg dose), or
20mg/mL (100mg/kg dose). Dose solutions were shown to be sta-
ble at concentrations ranging from 0.2 to 56.5mg/mL when stored
in polypropylene containers at 5 ◦C for up to 8 days andup to 24h at
room temperature. The dosing formulations used in these studies
were stored refrigerated and allowed to equilibrate to approx-
imately room temperature prior to dosing. Body weights were
recorded on the day of dosing only for dose volume calculations.
5mL/kg of the dosing solutionwere administered intravenously via
slow push injection into the marginal ear vein over approximately
2min. Blood (approximately 1mL)was collected from themarginal
ear vein or the auricular artery and semen was collected via use of
an artiﬁcial vagina at 8, 24, 48, and 72h after dosing. Blood sam-
ples were allowed to clot for approximately 30min, centrifuged
at approximately 2700 rpm for 10min and serum harvested and
stored at −80 ◦C until analysis. The volume of each semen sample,
minus theplug,was recordedprior to centrifugation toobtain semi-
nal plasma. Semen samples were vortexed for approximately 30 s
and then centrifuged (approximately 2700 rpm) for approximately
10min at room temperature to settle particulate matter. The semi-
nal plasma was withdrawn and stored at −80 ◦C until analysis. The
amount of T-IgG4 present in semen samples at each collection time
point was calculated as the seminal plasma concentration mul-
tiplied by the semen volume. Following the last collection time,
rabbits were euthanized by intravenous injection of sodium pen-
tobarbital.
Toxicokinetic analysis consisted of determination of serum and
seminal plasma concentrations of T-IgG4, the ratio of T-IgG4 in
serum to seminal plasma, the total seminal plasma T-IgG4 from
each semen sample, the total seminal plasma T-IgG4 from all four
semen samples, and the proportion of IV administered T-IgG4
recovered in seminal plasma from the four semen samples col-
lected over the 72h post-dosing period. Formulas for the calculated
endpoints are listed below.
Serum:seminal plasma ratio= concentration of T-IgG4 in
serum/concentration of T-IgG4 in seminal plasma.
Total seminal plasma T-IgG4 in each semen sample= seminal plasma
concentration of T-IgG4 in each ejaculate sample× semen volume.
Total seminal plasma T-IgG4 from all four semen sam-
ples= summation of the total seminal plasma T-IgG4 from
each of the four ejaculate samples collected over 72h.
Proportion of IV administered dose of T-IgG4 recovered in seminal
plasma= total seminal plasma T-IgG4 recovered over 72h/mg/kg
IV dose×kg body weight.
2.3. Intravaginal vs. intravenous absorption of T-IgG4 female
rabbits
Eight nonpregnant female NZW rabbits, approximately 6
months of age weighing approximately 2.9–3.6 kg, were randomly
assigned to two groups of four rabbits (6 or 100mg/kg) for the
intravaginal exposure assessment. Eight additional nonpregnant
female NZW rabbits of similar age and weight from a combined
fertility and embryo-fetal developmental toxicity study were ran-
domly assigned to two groups of four rabbits (6 or 100mg/kg) for
the intravenous exposure assessment. Bodyweightswere obtained
on Days 0 and 2 for the intravaginal dosed animals and Days 0
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nd 3 for the intravenous dosed animals. An T-IgG4 aqueous solu-
ion was prepared at appropriate concentrations in a matrix of
0mM sodium citrate, 150mMNaCl, and 0.02% Tween® 80 at a pH
f approximately 6.0. For intravaginal administration, the T-IgG4
olution was subsequently mixed with a vehicle gel (0.30% car-
opol 974P, 1.00%methylcellulose (4000 cps), 5.00%glycerin; 0.10%
ethylparaben; 0.05% propylparaben; and 93.55% puriﬁed water
or injection) at a ratio of approximately55:45 (T-IgG4 solution:gel)
o achieve the appropriate concentration necessary to deliver the
argeted dose on a mg/kg mean body weight basis using a dose
olume of 4mL/rabbit. The gel matrix was employed to slightly
ncrease the viscosity of the dosing solution in order to prevent
oss or drainage from the vagina following dosing. The ratio of T-
gG4 solution to gel remained constant across the two dose groups.
he ﬁnal T-IgG4dosing formulation remained as a solution andwas
dministered intravaginally as a single dose using a rubber catheter
t a volumeof 4mLper rabbit. For the intravenousgroup, thedosing
olution was administered as a single dose at a volume of 5mL/kg
ia the marginal ear vein using a 2min push.
Blood samples (approximately 1mL) were collected from the
arginal ear vein or auricular artery at 8, 24, and 48h after dosing.
dditional blood sampleswere taken from the intravenously dosed
abbits for extended duration toxicokinetics but are not reported
ere. Blood samples were processed and analyzed as previously
escribed. Following the last blood collection, all rabbits from the
ntravaginal dose groups were euthanized without necropsy. The
abbits from the intravenous dose groups remained on study for
ubsequent evaluation. Toxicokinetic parameters for T-IgG4 were
alculated from the individual rabbit serum concentration values
t each dosage level and interval.
.4. Maternal and fetal T-IgG4 exposure following IV
dministration
This maternal and fetal exposure study was part of a larger
ombined NZW rabbit fertility and embryo-fetal developmental
oxicity study. Nonpregnant rabbits approximately 7–8 months
f age and weighing approximately 2.9–3.9 kg were randomly
ssigned to each treatment group. For the main fertility and
mbryo-fetal developmental study, groups of 25 rabbits/treatment
ere administered 0 (vehicle control), 6, or 100mg/kg T-IgG4
eekly starting 14 days prior to mating and continuing through
estation day 21. An additional satellite group of 6 females were
dministered 100mg/kg T-IgG4 weekly at the same intervals as
he main study animals for maternal and fetal exposure assess-
ent on GD 21. Aqueous dosing solutions of T-IgG4 were prepared
n a matrix of 10mM citrate, 150mM NaCl, and 0.02% Tween
0; pH approximately 6.0. Because this study was part of a drug
egistration package conducted under Good Laboratory Practice,
ose formulations were analyzed for protein content for conﬁr-
ation that the targeted dose formulation concentrations were
chieved. Initial doses were administered via the marginal ear
ein at a volume of 5mL/kg via a slow push injection over a
eriod of approximately 2min. Due to adverse reactions and
ortality in some rabbits from the rate of infusion, the dose
dministration time was changed to approximately 15min using
n infusion pump. Following 2 weeks of treatment, the females
ere mated with males. For the main study phase females, blood
amples were collected prior to necropsy on gestation day 29,
hile the exposure satellite females had blood samples collected
rom three females each at approximately 8 or 24h following
ose administration on gestation day 21. Within 1h of collec-
ion of maternal blood for both main study and exposure satellite
emales, fetal blood was collected from each viable fetus per lit-
er. The blood volume collected from all adult females at each
ime point, as well as from all fetal litters was approximatelyxicology 48 (2014) 124–131
1.0mL. Blood was collected via a marginal ear vein for adult
females and from the umbilical veins of the fetuses into serum
separator tubes containing no anticoagulant; blood collected from
the fetuses was pooled by litter. All animals were euthanized
via an intravenous (adults) or subscapular (fetuses) injection of
sodium pentobarbital after completion of their respective study
periods.
3. Results
3.1. Seminal excretion of T-IgG4 in male rabbits
Data from the seminal excretion study are presented in Table 1.
All rabbits survived to scheduled termination and there were no
abnormal clinical ﬁndings noted at the daily examinations in any
group. Mean body weights were similar across all groups.
No measurable concentrations of T-IgG4 (all <0.0075g/mL)
were found in any of the serum samples from control animals
and therefore the control data were not tabulated. The majority
(17 of 20) of the seminal plasma samples from control animals
had concentrations of T-IgG4 that were below the quantita-
tion limit (<0.012g/mL). One sample had insufﬁcient volume
to assay, and two seminal plasma samples had concentrations
less than 0.050g/mL. Overall, the very low T-IgG4 concentra-
tions in two of the control (0mg/kg) seminal plasma samples
were not considered to have adversely impacted the toxicokinetic
evaluation.
Low levels of T-IgG4 were excreted into rabbit seminal plasma
following IV administration. Mean seminal plasma concentrations
of T-IgG4 ranged from 0.3 to 1.8g/mL in the 6mg/kg group and
from 1.9 to 12.2g/mL in the 100mg/kg group. The mean time to
maximum concentration (Tmax) for T-IgG4 in seminal plasma was
24h post-dose for both the 6 and 100mg/kg dose groups.
Mean serum concentrations of T-IgG4 ranged from 115 to
239g/mL in the 6mg/kg group and from 1746 to 2979g/mL
in the 100mg/kg group. The mean Tmax for T-IgG4 in serum was
8h post-dose for both the 6 and 100mg/kg dose groups, consis-
tent with the expected serum kinetics for an antibody following IV
administration.
Following single dose intravenous administration of 6 or
100mg/kg T-IgG4, both serum and seminal plasma exposure
increased in a slightly less thanproportionalmannerwith dose. The
mean maximum concentration (Cmax) of T-IgG4 in seminal plasma
increased seven-fold and serum Cmax increased 12-fold between
the doses of 6 and 100mg/kg.
At 8h post-dose in the 6mg/kg dose group, seminal plasma
concentrations of T-IgG4 were either low or below the limit of
quantitation (<0.012g/mL). At 100mg/kg, the 8-h post-dose ratio
of mean serum to mean seminal plasma T-IgG4 concentration
was 1599 to 1. From 24 to 72h post-dose in both the 6 and
100mg/kg groups, mean seminal plasma concentrations of T-IgG4
were found to be 101- to 372-fold less than mean serum con-
centrations. The high serum to seminal plasma ratios at the 8-h
post-dosing period indicated that there was a lag time in the dis-
tribution of T-IgG4 into the seminal vesicles following intravenous
administration.
The T-IgG4 dose delivered through semen was calculated by
multiplying the seminal plasma concentration by the match-
ing semen volume at each time point (Table 1). The total
dose delivered in semen from the four seminal plasma sam-
ples collected over a 72h period was calculated to be 1.92g in
males administered 6mg/kg and 15.04g in males administered
100mg/kg. The total T-IgG4 in the four seminal plasma samples
was 4–4.5 orders of magnitude less than the IV administered dose
(Table 1).
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3.2. Intravaginal vs. intravenous absorption of T-IgG4 female
rabbits
All rabbits survived to scheduled termination. There were no
clinical ﬁndings noted at the daily examinations in any group and
mean body weights were similar across all groups (data not pre-
sented).
Serum T-IgG4 exposure data following intravaginal and IV
administration are presented in Table 2. Following intravaginal
administration, T-IgG4 was poorly absorbed. At 6mg/kg intravagi-
nal, serum T-IgG4 was quantiﬁable (0.023g/mL) in only one of
four animals at a single time point (24h) post-dose. The remaining
serum samples from the 6mg/kg intravaginal group were below
the limit of quantitation (0.015g/mL). At 100mg/kg intravaginal,
serum T-IgG4 was quantiﬁable at all three time points in one of
four animals and at 24 and 48h post-dose in a second animal. The
remaining samples from the 100mg/kg intravaginal group were
below the limit of quantitation. The mean serum concentration
of T-IgG4 in the 100mg/kg intravaginal rabbit that had detectable
concentrations at all three time points was 0.577g/mL. The Cmax
in the vaginally dosed rabbits occurred 24h post-dosing.
Following IV administration, all animals given 6 or 100mg/kg
had detectable concentrations of T-IgG4 at all time points evalu-
ated. The mean concentration of T-IgG4 over the 48h evaluation
period in the IV dosed rabbits was 110g/mL at the 6mg/kg dose
and 1803g/mL at the 100mg/kg dose and increased approxi-
mately proportional to dose. When dose normalized, the mean
serumconcentrationwas18g/mLpermg/kgT-IgG4administered
for both the 6 and 100mg/kg groups.
The ratio of serumT-IgG4concentrationsbetween the intravagi-
nal and IV routes of administration was ≤0.00016 for the 6mg/kg
dose group and ≤0.00032 for the 100mg/kg dose group (Table 2).
Because most of the T-IgG serum concentrations were below the
limit of quantiﬁcation following intravaginal dosing, these ratios
were calculated using the highest available mean individual ani-
mal data for the intravaginally dosed animals, vs. the mean of four
animals following IV dosing. Given that most of the serum samples
from the intravaginal exposures were below the limit of quantita-
tion, these ratios represent a “worst case” calculation and indicate
systemic exposure via the vaginal route is at least 3.5 orders of
magnitude less than that obtained following intravenous exposure.
3.3. Maternal and fetal T-IgG4 exposure following IV
administration
The T-IgG4 concentration of each sampled dosing solution did
not deviate substantially from its theoretical value. Mean assayed
concentrations of T-IgG4 in the dosing solution were 100% of theo-
retical values. Formulations assessed for T-IgG4 concentration had
RSD values of ≤0.7% and were considered homogenous.
Compound-relatedmortality was noted in the 100mg/kg group
during the treatment period. In the main study group, 2 of 25
females died during the dosing process or shortly thereafter (3min
post-dose), one on GD 7 and one on GD 14. In the exposure satel-
lite group, two of six females given 100mg/kg were found dead,
one on GD 14 and one on GD 21. The causes of these deaths were
not determined butwere attributed to treatmentwith T-IgG4. Only
minor clinical signs of anogenital soiling and decreased defecation
were noted in some animals given 100mg/kg. Body weights were
unaffected by treatment (data not presented).
3.3.1. Gestational day 21 exposure assessment
Of the six females in the 100mg/kg GD21 satellite exposure
assessment (three were assigned to the 8-h post-dosing interval
and three were assigned to the 24-h post-dosing interval), only
two females, one at each sampling time-point, were available for
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Table 2
Serum T-IgG4a concentrations following intravaginal and intravenous exposure in nonpregnant rabbits.
Dose
(mg/kg)
Hours
post-dose
Intravaginal route Serum T-IgG4 concentration (g/mL) Ratio
Intravaginal:IV
concentrationb
Animal 66255 Animal 66256 Animal 66257 Animal 66259 Mean± SDa
6 8 BLQa BLQ BLQ BLQ NAa
24 BLQ BLQ BLQ 0.023 NA
48 BLQ BLQ BLQ BLQ NA
Mean NA NA NA <0.018c ≤0.00016
Animal 66251 Animal 66252 Animal 66254 Animal 66260 Mean± SD
100 8 0.479 BLQ BLQ BLQ NA
24 0.743 0.171 BLQ BLQ NA
48 0.510 0.022 BLQ BLQ NA
Mean 0.577 <0.097 NA NA ≤0.00032
Dose
(mg/kg)
Hours
post-dose
Intravenous route Serum T-IgG4 concentration (g/mL) Serum T-IgG4 (g/mL)
per mg/kg IV dose
(dose normalized)d
Animal 63642 Animal 63683 Animal 63686 Animal 63707 Mean± SD
6 8 145 171 130 158 151±17.6 25
24 109 114 94.6 98.4 104±9.3 17
48 76.7 87.1 62.3 79.5 76.4±10.4 13
Mean 110 124 95.6 112 110±11.6 18
Animal 63626 Animal 63628 Animal 63688 Animal 63702 Mean± SD
100 8 1755 2412 2282 1930 2095±305 21
24 1289 1614 1315 1474 1423±151 14
48 3968 1318 1079 1204 1892±1387 19
Mean 2337 1781 1559 1536 1803±373 18
a T-IgG4, experimental therapeutic humanized IgG4 monoclonal antibody; BQL, below the limit of quantitation (0.015g/mL); IV, intravenous; NA, not applicable; SD,
standard deviation.
b Intravaginal:intravenous T-IgG4 serum concentration ratios were calculated using the highest intravaginal serum values and the mean IV values.
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sc Mean intravaginal serum T-IgG4 for animal 66259 was calculated using values
d Dose normalized= concentration of T-IgG4 in serum (g/mL) divided by the do
xposure assessment (Table 3). The other four rabbits died (two
f six) or were not gravid (two of six). Maternal exposures were
236g/mL 8-h after dosing (Table 3) and 0.262g/mL 24-h after
osing (data not tabulated). There was no quantiﬁable exposure
o T-IgG4 in the fetuses at 8 or 24h post-dosing on gestation day
1 in the two animals evaluated, suggesting placental transfer was
ither limited at this stage of gestation or there was interference
rom anti-drug antibodies (ADA). In a previous pilot study it was
etermined that rabbits develop ADAs following repeated dosing
ith T-IgG4 (unpublished data)..3.2. Main study gestation day 29 exposure assessment
T-IgG4 concentrations were BLQ in all maternal and fetal sam-
les collected from the main study phase animals at 6mg/kg on
estation day 29, approximately 192h after the last dose, with the
able 3
lacental transfer: T-IgG4a concentrations in maternal and fetal serum.
Dose
(mg/kg)
Gestation day Time after
dosing (h)
Sample
100 21 8 1b
6 29 192 1d
100 29 192 15
a T-IgG4, experimental therapeutic humanized IgG4 monoclonal antibody; BLQ, below
b Only one of three females was conﬁrmed to be gravid and survived to gestation day 2
c Following weekly intravenous dosing, several rabbits had low or absent exposure to T
peciﬁcally measured.
d Of the surviving animals on gestation day 29, 16 of 17 dams and 16 of 17 matched po
e Mean± standard deviation.5g/mL (limit of quantiﬁcation) for time points with values BLQ.
inistered in mg/kg.
exception of one animal that had a maternal serum concentra-
tion of 10.7g/mL and a mean fetal concentration of 16.1g/mL
(Table 3). The low exposure at the 192h post-dose time period
is consistent with an ADA response, albeit ADAs were not specif-
ically measured in this study. The mean concentration of T-IgG4
in the fetuses was approximately 1.5× the respective maternal
concentration.
At 100mg/kg, serum T-IgG4 was quantiﬁable in 15 of 19 lit-
ters. The mean serum concentrations of T-IgG4 on GD29 were
268g/mL in maternal animals and 413g/mL in fetuses. Con-
sistent with the 6mg/kg data, the mean concentration of T-IgG4
in the fetuses was approximately 1.5× the respective maternal
concentrations indicating that T-IgG4 readily crosses the pla-
centa with slight accumulation in the fetuses toward the end of
gestation.
size T-IgG4 concentrations (g/mL) Fetal:maternal
ratio
Maternal Fetal
1236c BLQa ≤1.2×10−5
10.7 16.1 1.5
268±131e 413±169e 1.5
the quantiﬁcation limit of 0.015g/mL.
1.
-IgG4 consistent with an anti-drug antibody (ADA) response, albeit ADAs were not
oled fetal samples were BQL (<0.015g/mL) or had insufﬁcient sample.
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Table 4
Estimated fetal exposure following seminal excretion, vaginal absorption and placental transfer of a T-IgG4a antibody in rabbits.
IV dose to male
(mg/kg T-IgG4)
% of T-IgG4 dose in
semenb
Vaginal:IVa route
exposure ratioc
Serum T-IgG4
(g/mL) per mg/kg
IV dose (dose
normalized)d
GDa 29
fetal:maternal
T-IgG4 serum
ratioe
Estimated fetal
exposure from
seminal transfer on
GD 29f
Fetal exposure
ratio (seminal
transfer/maternal
IV)g
100 0.00408% ≤0.00032 18 1.5 3.5×10−5 g/mL 1.3×10−8
a T-IgG4, experimental therapeutic humanized IgG4 monoclonal antibody; IV, intravenous; NA, not applicable; SD, standard deviation; GD, gestation day.
b The percent of dose excreted in semen= total seminal plasma T-IgG4 recovered in four ejaculates over 72h/mg/kg IV dose×kg body weight of rabbit.
c Vaginal:IV exposure ratio = serum T-IgG4 concentration following a 100mg/kg intra-vaginal dose/serum T-IgG4 concentration following 100mg/kg IV dose.
d The dose normalized serum T-IgG4 concentration converts the dose administered on a mg/kg basis tog/mL of T-IgG4 in serum. This value was obtained by dividing the
measured serum T-IgG4 concentration by the mg/kg dose following IV administration of T-IgG4.
e Fetal:maternal T-IgG4 serum ratio = fetal serum T-IgG4 concentration/maternal serum T-IgG4 concentration on gestation day 29 following a 100mg/kg IV dose.
f Estimated fetal exposure from seminal transfer =100mg/kg IV dose to male×proportion of dose excreted in semen (0.000041)×vaginal:IV route exposure ratio
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f0.00032)×dose normalization factor (18) which converts IV dose equivalent to se
g Seminal transfer:maternal IV fetal exposure ratio = estimated fetal exposure fr
ale/(maternal exposure on GD29 (1803g/mL) following a 100mg/kg IV dose to
.4. Estimation of potential fetal exposure from excretion of
-IgG4 in semen
Combining the data from the seminal transfer, vaginal absorp-
ion, and placental transfer studies, an estimate of fetal exposure
rom T-IgG4 excreted into the semen and transferred to a pregnant
emale rabbit via vaginal deposition can be calculated (Table 4).
Male rabbits dosed at 100mg/kg IV were given 370mg T-IgG4
ased on an average body weight of 3.7 kg (Table 1).
100mg/kg · 3.7 kg=370mg or 370000g.
The proportion of a 100mg/kg IV dose of T-IgG4 excreted in
our semen samples collected over a 72h period was 4.08×10−5
Table 1).
15.09g T-IgG4 collected in four semen samples/370000g IV
dose =4.08×10−5 or
4.08×10−3% of T-IgG4 dose eliminated in semen over 72h period.
The proportion of T-IgG4 absorbed following vaginal exposure
as estimated by calculating the vaginal route:IV route serum con-
entration ratio following doses of 100mg/kg (Table 2).
0.577g/mL vaginal route/1803g/mL IV route =3.2×10−4.
The estimated dose absorbed systemically in the female follow-
ng vaginal administration is the dose administered to the male
imes the proportion of the administered dose transferred into
emen times the proportion of drug that is systemically available
n females after vaginal absorption=1.31×10−6 mg/kg.
100mg/kg ·4.08×10−5 ·3.2×10−4 =1.31×10−6 mg/kg.
Because a 1.31×10−6 mg/kg systemic dose of T-IgG4 would
esult in serum concentrations below the limit of detection
0.015g/mL), a dose normalization factor was used to calculate
he resulting serum exposure. The dose normalization factor con-
erts IV dose administered on a mg/kg basis to serum exposure on
g/mL basis (Table 2). For every mg/kg dose administered by IV
dministration, the serum concentration of T-IgG4 was estimated
o be 18g/mL. This dose normalized T-IgG4 serum concentration
s based on the assumption that T-IgG4 concentrations remained
airly constant up to 48h postdose. The average T-IgG4 serum
xposure over a 48h interval resulting from a 1.31×10−6 mg/kg
ntravaginal dose of T-IgG4was calculated to be 2.36×10−5g/mL.1.31×10−6 mg/kg ·18g/mL/mg/kg=2.36×10−5g/mL.
The ﬁnal factor in estimating fetal exposure from seminal trans-
er is the calculation of the fetal:maternal T-IgG4 serum ratioxposure× fetal:maternal T-IgG4 serum ratio (1.5).
minal transfer on GD29 (3.5×10−5 g/mL) following a 100mg/kg IV dose to the
ale×GD29 fetal:maternal T-IgG4 serum ratio (1.5)).
(Table 3). The fetal: maternal T-IgG4 serum ratio on GD29 at 192h
postdose was 1.5. For calculation purposes, we have assumed that
the ratio of maternal/fetal systemic exposure to T-IgG4 does not
change from0 to192hpost-dose. This is a simpliﬁcation, but allows
for a conservative estimate of fetal exposure following maternal
dosing of T-IgG4.
Putting it all together, the estimate of fetal serum exposure
resulting from a 100mg/kg dose of T-IgG4 to the male (excretion
of T-IgG4 into semen, vaginal absorption of T-IgG4, and placental
transfer to the fetus) is calculated to be 3.5×10−5g/mL (Table 4).
100mg/kg ·4.08×10−5 ·3.2×10−4 ·18g/mL per mg/kg
dose ·1.5 =3.5×10−5g/mL.
The fetal exposure ratio following seminal transfer of T-IgG4 rel-
ative to direct IV dosing of the pregnant femalewas estimated to be
1.3×10−8 (Table4). This valuewasdeterminedbydividing theesti-
mated fetal serum T-IgG4 concentration from seminal transfer by
the product of themeasuredmaternal GD29 serum T-IgG4 concen-
tration and the GD29 fetal: maternal serum T-IgG4 concentration
ratio.
3.5×10−5g/mL/(1803g/mL ·1.5) =1.3×10−8.
4. Discussion
As reviewed by Klemmt and Scialli [2], there are three potential
mechanisms for exposure to the conceptus from drugs in semen.
These transport mechanisms include: (1) absorption from the
vagina into the maternal circulation followed by placental trans-
fer to the conceptus, (2) direct exposure to the conceptus following
physical transfer through the cervix and into the uterine cavity, and
(3) direct delivery to the egg via adsorption or binding to sperm.
Although largemolecular weight IgGs (150kDa) are not thought to
readily diffuse through cellular membranes as observedwith small
molecular weight (<1000Da) organicmolecules, IgGs are known to
cross cellular membranes through a transcytotic, FcRn-mediated
transportmechanism[6,7]. Li et al. [8] demonstrated that FcRngene
expression was present in epithelial cells within the female genital
tract (cervical, uterine, and vaginal) of humans and mice and that
FcRn bound IgG in these tissues. The authors further demonstrated
FcRn mediated bidirectional IgG transport across human endome-
trialmonolayers andprimaryhumangenital epithelial cells in vitro.
When IgG was introduced vaginally to wild type (WT) and FcRn-
knock out (FcRn-KO) mice, IgG was readily detected in the sera of
WT mice but not in the sera of FcRn-KO mice, supporting the posi-
tion that IgG absorption from the genital tract is FcRn-mediated
and a potential pathway for conceptus exposure following semi-
nal transfer. Conversely, exposure of the conceptus to IgG drugs
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hrough cervical translocation or adsorption/binding to the sperm
s not considered to represent a signiﬁcant concern as cervical
ucus ﬁlters out seminal plasma from spermatozoa and acts as a
arrier to large molecules [9,10]. Furthermore, the quantity of IgG
rug potentially adhering/binding to the surface of the spermato-
oa is expected to be small or nonexistent given the highly selective
inding characteristics of most antibody drugs, the extremely low
xpression of FcRn in the testes [11], and therefore on the surface of
permatozoa, and the relatively small size and limited IgG carrying
apacity of the spermatozoa.
To assess potential exposure risk to the conceptus from excre-
ion of a T-IgG4 antibody into semen, systemic absorption from
he vagina, and placental transfer to the fetus, data from a series
f studies using the rabbit as a model were analyzed. In the
rst study, blood (serum) and seminal plasma samples for T-IgG4
oncentration determination were collected from male rabbits
ollowing a single 6 or 100mg/kg IV dose of T-IgG4. The concen-
rations of T-IgG4 in seminal plasma ranged from 0.3 (6mg/kg)
o 12.2 (100mg/kg)g/mL from 24 to 72h post-dosing. The
erum:seminal T-IgG4 ratio ranged from approximately 100–370,
ndicating relatively low levels of T-IgG4were secreted into semen.
he concentrations of T-IgG4 in rabbit seminal plasma and the
abbit T-IgG4 serum:seminal plasma ratios were similar to those
eported for endogenous IgG4 in healthy human volunteers. Raux
t al. [12] reported total IgG4 serum and seminal secretion con-
entrations of 517g/mL and 1.6g/mL, respectively, resulting
n a serum:seminal secretions ratio of 323. Raux et al. [12] also
eported similar human serum:seminal concentrations ratios for
gG1 (317:1) and IgG2 (310:1), but a higher ratio for IgG3 (1425:1),
ndicating that all IgG subtypes are excreted at relatively low lev-
ls in semen. Similarly, other investigators have reported total
ndogenous IgG serum and semen concentrations that produced a
erum:semen ratio of approximately 115 in normospermatic men
13]. The consistency between the rabbit T-IgG4 and the human
ndogenous IgG4 data, along with the human total IgG data, sug-
est that there is likelynodifferencebetween the seminal excretion
f therapeutic and endogenous IgG antibodies and that the rabbit
s a useful model for predicting excretion of T-IgG antibodies into
uman semen.
The total amount of T-IgG4 excreted in four semen samples col-
ected over 72h in the rabbit, based on T-IgG4 seminal plasma
oncentrations multiplied by the semen volumes, was estimated
o be 0.004–0.009% of the administered dose. Given the congru-
nce between excretion of IgG4 into rabbit and human seminal
lasma, and the relatively small volume (1–5mL) of semen ejac-
lated in humans, the transfer of T-IgG4 drugs through semen in
umans would also be expected to be relatively small, approxi-
ately four-orders of magnitude less than the dose administered
o the male.
In the second experiment, a T-IgG4 solution was vaginally
dministered to nonpregnant female rabbits at doses of 6 and
00mg/kg. In order to maximize the time the T-IgG4 remained
n contact with the vaginal epithelium, the formulation for the
aginally administered T-IgG4 was modiﬁed to slightly increase
iscosity and prevent it from quickly draining from the vagina.
ollowing dosing, visual observations were made that conﬁrmed
ittle to no dosing solution was lost to drainage. The prolonged
etention of the dosing solution represents aworst case scenario as
necdotal evidence indicates human semen is not readily retained
ntravaginally. Although Li et al. [8] demonstrated that there were
cRn-mediated transport mechanisms in the vagina, the results
rom our vaginal absorption study indicate that minimal absorp-
ion of T-IgG4 occurred following vaginal dosing, as mean serum
-IgG4 concentrationsmeasured over a 48h period following vagi-
al absorptionwereapproximately0.032%of serumconcentrations
ollowing IV injection. It is acknowledged that the vaginally dosedxicology 48 (2014) 124–131
rabbitswere nonpregnant and potential differences in vaginal FcRn
concentrations between the nonpregnant and pregnant state could
be a source of variability for vaginal absorption.
In the ﬁnal placental transfer study, rabbits demonstrated low
placental transfer of T-IgG4 on GD21 (below the quantiﬁcation
limit), but high transfer on GD29, with GD29 fetal serum T-IgG4
concentrations 1.5-fold higher than maternal serum T-IgG4 con-
centrations. The small sample size (one litter) and the interference
from antidrug antibodies may have confounded the GD21 placen-
tal transfer data. Currently, it is not knownwhethermaternal ADAs
affect thematernal:fetal IgG4 serumconcentration ratios in rabbits.
However, lower rates of IgG placental transfer are known to occur
in rabbits and primates earlier in gestation. It is also unknown
whether maternal ADA impact the maternal:fetal IgG ratios. Bow-
man et al. [14] reported that rabbit fetal serum IgG concentrations
rose 600-fold from GD19 to GD28, reaching or exceeding maternal
serum concentrations on GD28. Similarly, as reviewed by Pentsuk
and van der Laan [15], increasing rates of placental transfer of IgG
antibodies were reported as gestation progressed in humans, with
no or very low levels of IgG in the embryonic/fetal compartment
during the early second trimester. As observedwith rabbits, human
late fetal and infant IgG concentrations reached or exceededmater-
nal concentrations [15]. Based on the similarities between rabbit
and human placental transfer of IgG antibodies during the mid-
late (secondand third trimester equivalent) gestational periods, the
rabbit appears to be a good model for assessing placental transfer
risk in humans during the fetal period. There is currently insufﬁ-
cient information in both rabbits and humans to assess the utility
of the rabbit model in predicting early embryonic (ﬁrst trimester
equivalent) placental transfer of IgG antibodies in humans [14].
Combining the data from the seminal transfer, vaginal absorp-
tion, and placental transfer studies, the estimated exposure to the
conceptus from the seminal transfer of T-IgG4 drug is extremely
low and T-IgG4 is unlikely to be present in the embryo/fetus at
concentrations sufﬁcient to produce a biological response. Using
the rabbit as a model, the amount of drug delivered in semen from
multiple ejaculates over a 72h period is approximately 0.00408% of
the dose administered to themale. The amount of T-IgG4 absorbed
from the vagina is also extremely low, approximately 0.032% of the
vaginal dose delivered. Using this data, along with the dose nor-
malization factor of 18 to convert dose administered on a mg/kg
basis to blood exposure on a g/mL basis, and adjusting for the
fetal:maternal GD29 serum concentration ratio of 1.5-fold, the
estimated GD29 fetal T-IgG4 serum concentration resulting from
seminal transfer following a 100mg/kg dose to the male would
be approximately 3.5×10−5g/mL, and approximately 1.3×10−8
times less than the exposure when the pregnant female was dosed
via IV injection (Table 4). These exposuremultipleswould be signif-
icantly below any therapeutic or biologically active levels of T-IgG4
(see discussion below).
To support the position of low embryo/fetal exposure risk
from seminal transfer of T-IgG4 drug, human data were applied
to the model. Using the maximum dose administered in clinical
trials with T-IgG4, the highest serum exposures (Cmax) were
≤50g/mL (unpublished data). Given the T-IgG4 serum:seminal
plasma concentration ratios of 100–370 in the rabbit, and the
similar ﬁndings with endogenous IgG/IgG4 in humans [12], the
human semen concentration can be conservatively estimated
to be approximately 0.50g/mL (50g/mL×1/100). Using a
maximum semen volume of approximately 5mL for man [16], the
dose delivered vaginally is 2.5g (0.5g/mL×5mL). Applying
the vaginal absorption factor of 0.00032 obtained in rabbits, the
dose absorbed by the female is 0.0008g (0.00032×2.5g).
The 0.0008g vaginally absorbed dose is equivalent to a
1.14×10−8 mg/kg dose using a 70kg female (0.0008g/70kg
body weight×1mg/1000g). The human fetal exposure
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rom the maternal dose is estimated to be 3.07×10−7g/mL
y converting maternal systemic dose into plasma concen-
ration and adjusting for the embryo:maternal serum ratio
1.14×10−8 mg/kg×18g/mL/mg/kg×1.5 fetal:maternal serum
atio). For this T-IgG4, the effective human concentrations pro-
ucing a 20% (EC20) or 80% (EC80) inhibition of the target is
pproximately 0.8g/mL and 12.4g/mL, respectively (unpub-
ished data). The dissociation constant (Kd) for the T-IgG4 and
ts human ligand is 5.9×10−4g/mL. The estimated human fetal
erum concentration of 3.07×10−7g/mL resulting from seminal
ransfer of T-IgG4, when administered at the highest proposed
linical dose, is at least 1000-fold lower than the Kd and at least
even orders of magnitude lower that the human EC20. Therefore,
he estimated human fetal exposure to T-IgG4 from seminal
ransfer is insufﬁcient to produce a biologic response and would
ot represent a meaningful human risk. It should also be noted
hat this exposure estimate represents a worst-case scenario as
he most conservative values were applied in the assessment and
lacental transfer of IgG during the critical embryonic period of
evelopment is considered to be signiﬁcantly less than the late
estational placental transfer values utilized in the calculations.
. Conclusion
Relatively low levels of T-IgG4 antibodywere excreted into rab-
it semen,with concentrations ranging from100- to370-fold lower
han the concentrations observed in serum. The serum:semen con-
entrations ratios for T-IgG4 in rabbit were similar to endogenous
gG4 and total IgG serum:semen concentration ratios reported for
umans; therefore, the rabbit appears tobeagoodpredictivemodel
or assessing the potential for excretion of IgG4 antibody drugs
nto human semen. The low concentration of T-IgG4 excreted into
emencombinedwith the small volumeof semenejaculated results
n a low delivered dose to the female, approximately 4–4.5 orders
f magnitude lower than the therapeutic dose administered to the
ale by IV injection. Vaginal absorption of T-IgG4 was also low,
pproximately 3.5 orders of magnitude lower than IV administra-
ion. The rabbit GD29 fetal T-IgG4 exposure from excretion of drug
nto the semen of a male dosed (IV) at 100mg/kg was estimated
o be extremely low (3.5×10−5g/mL) and approximately eight
rders of magnitude below the fetal exposure following a direct
00mg/kg IV dose to a pregnant female rabbit. Applying human
erumT-IgG4 exposure data to themodel, using thehighest applied
uman dose, the estimated human fetal serum concentration from
eminal transfer of T-IgG4 was 3.07×10−7g/mL, a level at least
000-fold lower than the Kd and at least seven orders ofmagnitude
ower that the human in vivo EC20. These data indicate that excre-
ion of this T-IgG4 into semen would not result in any biologically
eaningful exposure risk to the conceptus of an untreated partner.
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